

ASX RELEASE (22 JUNE 2020)

THC Global Completes \$6.6 million Institutional Placement

Investment Highlights:

- \$6.6 million placement completed with significant demand received from new institutional investors with positive long term views on the Company
- Stronger share register with better institutional representation and stronger balance sheet
- Share Purchase Plan launch, offering all eligible shareholders the opportunity to apply for up to \$30,000 in new shares at the same price as the Placement
- Placement funds to support working capital and enable acceleration of high volume cannabis medicines production for Australian patients and the global export market

THC Global Group Limited (**THC Global** or the **Company**) (ASX:THC) has successfully completed a \$6.6 million placement offered to institutional and sophisticated investors at \$0.30 per share, resulting in the issue of approximately 22 million new Shares (the **Placement**). MST Financial acted as Lead Manager to the Placement.

The Company received strong demand from new institutional investors as well as sophisticated and wholesale investors. In offering the Placement to new institutional investors, the Company and MST Financial looked to identify institutions with a long term view and alignment with the Company's strategic focus towards cannabis pharmaceuticals.

Commenting on the Placement, Ken Charteris, THC Global's Chief Executive Officer commented:

"We are pleased with the significant interest we received from institutional, sophisticated, and wholesale investors through this Placement. We now have a stronger share register with better institutional representation, and a stronger balance sheet to take us forward through this period of scaling up our cannabis pharmaceutical operations."

In addition to the Placement, the Company will offer all eligible shareholders in Australia and New Zealand the opportunity to apply for up to \$30,000 of new shares in the Company at the same price as the Placement under a Share Purchase Plan (the **SPP**). The Company will provide further information on the SPP on Thursday, 25 June, being the expected open date of the SPP, including details on how eligible shareholders can participate.

Due to COVID-19, shareholders who elect to have their SPP documentation sent by post may experience delays in receiving their documentation. Accordingly, the Company strongly recommends shareholders ensure that their email address has been provided to Computershare, the Company's Share Registry, as Computershare will be managing the SPP application process. Please contact Computershare on +61 (0)3 9415 4000 or 1300 850 505 (within Australia) to update your details. Shareholders who have provided Computershare with their email address will receive a link to access the SPP documentation by email immediately following the open of the offer. Additionally, the Company will also enable Shareholders to participate in the SPP by completing an online application, with details to be provided on the open date.

An indicative timetable for the completion of the Placement and launch of the SPP is below.

Event	Indicative Date
Record Date for SPP	Friday, 19 June 2020
Announcement of Placement and SPP	Monday, 22 June 2020
SPP Opens and Documentation Sent	Thursday, 25 June 2020
Placement Settlement and Issue of Placement Shares	Friday, 26 June 2020
ASX Quotation of Placement Shares	Monday, 29 June 2020
SPP Closes	Friday, 10 July 2020
Announcement of Demand and Scale Back	Friday, 17 July 2020
Allotment and Issue of SPP Shares	Monday, 20 July 2020
ASX Quotation of SPP Shares	Tuesday, 21 July 2020
Dispatch of Shareholder Statements for SPP Participants	Thursday, 23 July 2020
Indicative timetable and is subject to change without notice. The Company reserves the right to vary the dates above, subject to any regulatory or statutory provisions that may apply.	

The Placement and SPP funds will be applied towards working capital for the Company's existing operations and supporting the acceleration of the Company's cannabis medicines manufacturing at its Southport Facility, as it targets 6,000 patients using THC Global produced cannabis medicines by the end of 2020. Following settlement of the Placement, the Company's group consolidated cash balance will be approximately \$9.3 million after costs of the raising. Funds raised under the SPP will further strengthen the Company's balance sheet.

Securities to be issued under the Placement will be issued under the remaining capacity the Company has pursuant to ASX Listing Rule 7.1 and the additional placement capacity made available pursuant to the ASX's 'Class Waiver Decision – Temporary Extra Placement Capacity' which the Company relied upon in conducting the Placement and SPP.

For further information, please contact:



Ken Charteris
 Chief Executive Officer
 e: ceo@thc.global

Sonny Didugu & Jarrod White
 Joint Company Secretaries
 e: corporate@thc.global
 p: +61 2 8088 4760

The Capital Network
 Julia Maguire
 e: julia@thecapitalnetwork.com.au
 p: + 61 2 8999 3699

ASX release authorised by THC Global's Management Committee – the Chairman, Deputy Chairman, and CEO.

THC Global Group Limited (ASX: THC) thc.global

THC Global is a diversified global cannabis company with primary operations in Australia and Canada. THC Global is the first ASX listed entity to fully own and operate end to end commercial medicinal cannabis production facilities under Australia's cannabis regulations. THC Global's Southport Facility is one of the largest pharmaceutical GMP cannabis manufacturing facilities in the world. THC Global also owns and operates Crystal Mountain, a fast growing hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sector in North America and Europe.

For prospective patients or healthcare professionals seeking more information on medicinal cannabis, please visit: canndeocare.com and tetrahealth.com.au.